Company news

Neuren Pharmaceuticals Limited news in 2016

Neuren Pharmaceuticals Limited's news releases, calls and decks from 2016, newest first.

View company

Neuren IND open for Rett Phase II trial

February 10, 2016

Neuren confirms orphan drug designations in Europe

February 10, 2016

Neuren completes Phase I NNZ2566 study/files Phase II IND

February 10, 2016

Neuren completes enrolment in Phase 2 trial in Rett Syndrome

February 10, 2016

Neuren completes enrolment in INTREPID clinical trial

February 10, 2016

Neuren announces Renounceable Rights Issue

February 10, 2016

Neuren Announces Private Placement and Rights Issue

February 10, 2016

Neuren announces cancer xenograft testing results

February 10, 2016

Neuren advances NNZ-2591 towards IND application

February 10, 2016

IRSF confirms financial support for Neurens clinical trials

February 10, 2016

Half Yearly Report and Accounts 30 June 2015

February 10, 2016

Grant of composition patent in Europe for Neurens NNZ-2591

February 10, 2016

FDA grants Neuren Orphan Drug designation for Rett syndrome

February 10, 2016

FDA Fast Track granted for NNZ2566 Rett program

February 10, 2016

Enrolment commences in Neurens Concussion Phase 2 trial

February 10, 2016

← Newer news releases

Decks in 2016